User:Mr. Ibrahem/Tasimelteon

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Tasimelteon
Clinical data
Trade namesHetlioz, Hetlioz LQ
AHFS/Drugs.comMonograph
MedlinePlusa615004
License data
Dependence
liability		None[1]
Addiction
liability		None[1]
Routes of
administration		By mouth
Drug classMelatonin receptor agonist[1]
Legal status
Legal status
Pharmacokinetic data
Bioavailabilitynot determined in humans[2]
Protein binding89–90%
Metabolismextensive liver, primarily CYP1A2 and CYP3A4-mediated
Elimination half-life0.9–1.7 h / 0.8–5.9 h (terminal)
Excretion80% in urine, 4% in feces
Identifiers
  • (1R, 2R)-N-[2-(2,3-dihydrobenzofuran-4-yl)cyclopropylmethyl]propanamide
Chemical and physical data
FormulaC15H19NO2
Molar mass245.322 g·mol−1
3D model (JSmol)
  • CCC(=O)NC[C@@H]1C[C@H]1C2=C3CCOC3=CC=C2
  • InChI=1S/C15H19NO2/c1-2-15(17)16-9-10-8-13(10)11-4-3-5-14-12(11)6-7-18-14/h3-5,10,13H,2,6-9H2,1H3,(H,16,17)/t10-,13+/m0/s1 ☒N
  • Key:PTOIAAWZLUQTIO-GXFFZTMASA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Tasimelteon, sold under the brand name Hetlioz among others, is a medication used to treat non-24-hour sleep–wake disorder.[1] It is taken by mouth, an hour before bedtime.[1][3] Benefits may take months to occur.[1]

Common side effects include headache, sleepiness, nausea, and dizziness.[3] Safety in pregnancy is unclear.[1] It works by activating the melatonin receptor.[3]

Tasimelteon was approved for medical use in the United States in 2014 and Europe in 2015.[1][3] In the United States it costs about 23,000 USD per month as of 2021.[4] Despite being approved in Europe and available in Germany it is not sold in the United Kingdom as of 2021.[5]

References[edit]

  1. ^ a b c d e f g h i j "Tasimelteon Monograph for Professionals". Drugs.com. Archived from the original on 4 November 2020. Retrieved 22 September 2021.
  2. ^ "Tasimelteon Advisory Committee Meeting Briefing Materials" (PDF). Vanda Pharmaceuticals Inc. November 2013. Archived (PDF) from the original on 2013-11-25. Retrieved 2020-12-03.
  3. ^ a b c d e "Hetlioz EPAR". European Medicines Agency (EMA). Archived from the original on 3 November 2020. Retrieved 2 December 2020.
  4. ^ "Hetlioz Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 13 August 2021. Retrieved 22 September 2021.
  5. ^ "Tasimelteon". SPS - Specialist Pharmacy Service. Archived from the original on 30 November 2020. Retrieved 22 September 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Tasimelteon&oldid=1215650003"